PT - JOURNAL ARTICLE AU - Mades, Aubree AU - Chellamathu, Prithivi AU - Lopez, Lauren AU - Kojima, Noah AU - MacMullan, Melanie A. AU - Denny, Nicholas AU - Angel, Aaron N. AU - Casian, Joseph G. AU - Brobeck, Matthew AU - Nirema, Nina AU - Klausner, Jeffrey D AU - Turner, Frederick AU - Slepnev, Vladimir I. AU - Ibrayeva, Albina TI - Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination AID - 10.1101/2021.05.06.21256403 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.06.21256403 4099 - http://medrxiv.org/content/early/2021/05/07/2021.05.06.21256403.short 4100 - http://medrxiv.org/content/early/2021/05/07/2021.05.06.21256403.full AB - Previous studies have shown that mRNA COVID-19 vaccines are highly effective at preventing SAR-CoV-2 infection by generating an immune response, which in part produces SARS-CoV-2 IgG antibodies in serum. In this study, we hypothesized that COVID-19 vaccines may elicit production of SARS-CoV-2 IgG antibodies in the upper respiratory tract, such as in oral and nasal mucosal fluid. To test that hypothesis, we enrolled 114 participants within 3-7 days of receiving the first dose of the Moderna mRNA COVID-19 vaccine and collected oral mucosal fluid samples on days 5, 10, 15, and 20 after each vaccine dose. Of participants naive to SARS-CoV-2 (n = 89), 79 (85.4%) tested positive for SARS-CoV-2 IgG antibodies by time point 2 (10 days +/-2 days after first vaccine dose), and 100% tested positive for SARS-CoV-2 IgG by time point 3 (15 days +/-2 days after first vaccine dose). Additionally, we collected paired oral mucosal fluid and anterior nares samples from 10 participants who had received both vaccine doses. We found that participants had an average SARS-CoV-2 IgG antibody concentration of 2496.0 +/-2698.0ng/mL in nasal mucosal fluid versus 153.4 +/-141.0ng/mL in oral mucosal fluid. Here, we demonstrate detection and longitudinal persistence of SARS-CoV-2 IgG antibodies in upper respiratory tract specimens following COVID-19 mRNA vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Curative Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the Advarra Institutional Review Board (IRB# Pro00048737 and Pro00045766).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request from Corresponding AuthorOSCDOraSure® Technologies Oral Specimen Collection DevicerRT-PCRReal-time reverse transcription polymerase chain reactionELISAEnzyme-Linked Immunosorbent AssayCOVID-192019 novel coronavirusRNAribonucleic acidmRNAMessenger ribonucleic acidIgAImmunoglobulin AIgGImmunoglobulin GIgMImmunoglobulin MSARS-CoV-2Severe acute respiratory syndrome coronavirus 2LODLimit of DetectionLOQLimit of Quantification